CD19-directed CAR T cells could achieve complete remissions in up to 90% of patients with relapsed B-ALL [39], whereas durable anti-tumor responses were observed in only 26% of CLL patients infused with CAR T cells targeting CD19 [50]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.